지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한병리학회 Journal of Pathology and Translational Medicine Journal of Pathology and Translational Medicine 제56권 제6호
- 발행연도
- 2022.11
- 수록면
- 326 - 333 (8page)
- DOI
- 10.4132/jptm.2022.10.17
이용수
초록· 키워드
오류제보하기
Every patient with advanced non–small cell lung cancer (NSCLC) should be tested for targetable driver mutations and gene arrangements that may open avenues for targeted therapy. As most patients with NSCLC in the advanced stage of the disease are not candidates for surgery, these tests have to be performed on small biopsies or cytology samples. A growing number of other genetic changes with targetable mutations may be treatable in the near future. To identify patients who might benefit from novel targeted therapy, relevant markers should be tested in an appropriate context. In addition, immunotherapy of lung cancer is guided by the status of programmed death-ligand 1 expression in tumor cells. The variety and versatility of cytological specimen preparations offer significant advantages for molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is important, not only from a lung cancer diagnosis, but also for the large number of ancillary studies that are necessary to provide appropriate clinical management. A large proportion of lung cancers is diagnosed by aspiration or exfoliative cytology specimens; thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. In this review, we discuss the opportunities and challenges of using cytologic specimens for biomarker testing of lung cancer and the role of cytopathology in the molecular era.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
비소세포폐암 환자의 표적 치료
대한내과학회지
2024 .04
-
Epidemiology of Lung Cancer in Korea: Recent Trends
Tuberculosis and Respiratory Diseases
2016 .01
-
Clinical Usefulness of Human Epididymis Protein 4 in Lung Cancer
Annals of Laboratory Medicine
2017 .01
-
비소세포폐암의 새로운 표적치료
대한의사협회지
2023 .03
-
Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing
Journal of Pathology and Translational Medicine
2015 .01
-
Immunotherapy for Non-small-cell Lung Cancer : Current Status and Future Obstacles
Immune Network
2017 .12
-
Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment
Cancer Research and Treatment
2019 .01
-
폐암의 바이오마커와 진단도구
대한의사협회지
2021 .01
-
폐암 정복을 위한 전방위적 반격
대한의사협회지
2023 .03
-
Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure
대한직업환경의학회지
2016 .03
-
Clinical Efficacy and Possible Applications of Genomics in Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Animal models and therapeutic molecular targets of lung cancer
한국실험동물학회 학술발표대회 논문집
2019 .01
-
국가 폐암 검진
대한내과학회지
2020 .04
-
Expression of potassium channel genes predicts clinical outcome in lung cancer
The Korean Journal of Physiology & Pharmacology
2019 .01
-
Risk Factors for Lung Cancer Mortality in a Referral Center
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Molecular biomarker testing for non?small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2021 .01
-
비소세포폐암의 표적 치료
대한내과학회지
2020 .04
-
Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study
Cancer Research and Treatment
2018 .01
-
Double primary lung adenocarcinoma diagnosed by epidermal growth factor receptor mutation status
Journal of Yeungnam Medical Science
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0